# Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis

> **NCT06360861** · PHASE1 · COMPLETED · sponsor: **Tehran University of Medical Sciences** · enrollment: 5 (actual)

## Conditions studied

- Multiple Sclerosis
- Secondary-Progressive Multiple Sclerosis
- Mesenchymal Stem Cells

## Interventions

- **BIOLOGICAL:** Allogenic placenta derived mesenchymal stem cells

## Key facts

- **NCT ID:** NCT06360861
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-23
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-03-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06360861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06360861, "Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06360861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*